Antihypertensive treatment of acute cerebral hemorrhage*
Year: 2010
Type: article
Study design: Clinical Trial
Abstract: OBJECTIVE: To determine the feasibility and acute (i.e., within 72 hrs) safety of three levels of systolic blood pressure reduction in subjects with supratentorial intracerebral hemorrhage treated within 6 hrs after symptom onset. DESIGN: A traditional phase I, dose-escalation, multicenter prospective study. SETTINGS: Emergency departments and intensive care units. PATIENTS: Patients with intracerebral hemorrhage with elevated systolic blood pressure > or = 170 mm Hg who present to the emergency department within 6 hrs of symptom onset. INTERVENTION: Intravenous nicardipine to reduce systolic blood pressure to a target of: (1) 170 to 200 mm Hg in the first cohort of patients; (2) 140 to 170 mm Hg in the second cohort; and (3) 110 to 140 mm Hg in the third cohort. MEASUREMENTS AND MAIN RESULTS: Primary outcomes of interest were: (1) treatment feasibility (achieving and maintaining the systolic blood pressure goals for 18-24 hrs); (2) neurologic deterioration within 24 hrs; and (3) serious adverse events within 72 hrs. Safety stopping rules based on neurologic deterioration and serious adverse events were prespecified and approved by an NIH-appointed Data and Safety Monitoring Board, which provided oversight on subject safety. Each subject was followed-up for 3 months to preliminarily assess mortality and the clinical outcomes. A total of 18, 20, and 22 patients were enrolled in the respective three tiers of systolic blood pressure treatment goals. Overall, 9 of 60 patients had treatment failures (all in the last tier). A total of seven subjects with neurologic deterioration were observed: one (6%), two (10%), and four (18%) in tier one, two, and three, respectively. Serious adverse events were observed in one subject (5%) in tier two and in three subjects (14%) in tier three. However, the safety stopping rule was not activated in any of the tiers. Three (17%), two (10%), and five (23%) subjects in tiers one, two, and three, respectively, died within 3 months. CONCLUSIONS: The observed proportions of neurologic deterioration and serious adverse events were below the prespecified safety thresholds, and the 3-month mortality rate was lower than expected in all systolic blood pressure tiers. The results form the basis of a larger randomized trial addressing the efficacy of systolic blood pressure reduction in patients with intracerebral hemorrhage.
Source: Critical Care Medicine
Author: Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators
Institutions: University of Minnesota, Medical University of South Carolina
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: intracerebral hemorrhage, antihypertensive therapy, systolic blood pressure reduction, nicardipine, intravenous antihypertensive therapy, neurological deterioration, treatment safety, dose escalation, mortality, acute stroke care, supratentorial hemorrhage, blood pressure targets, serious adverse events, treatment feasibility, data safety monitoring board
Open Access status: green
Awards: Statistical and Data Coordinating Center for ALIAS and IMS 111 Trials, Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage, G3543592251, G452026546, Antihypertensive Treatment in Acute Cerebral Hemorrhage, G5290935616, ProTECT III, Neurological Emergencies Treatment Trial Network Statistical/Data Management Ctr
OpenAlex ID: W2561826548
